Literature DB >> 5443406

Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs.

W H Inman, M P Vessey, B Westerholm, A Engelund.   

Abstract

Reports of thromboembolism following the use of oral contraceptives received by drug safety committees in the United Kingdom, Sweden, and Denmark have been analysed to investigate possible differences in the risks associated with the various preparations. For this purpose the numbers of reports of thromboembolism attributed to each product were compared with the distribution that would have been expected from market research estimates of sales, assuming that all products carried the same risk.A positive correlation was found between the dose of oestrogen and the risk of pulmonary embolism, deep vein thrombosis, cerebral thrombosis, and coronary thrombosis in the United Kingdom. A similar association was found for venous thrombosis and pulmonary embolism in Sweden and Denmark. No significant differences could be detected between sequential and combined preparations containing the same doses of oestrogen, nor between the two oestrogens, ethinyloestradiol and mestranol.Certain discrepancies in the data suggest that the dose of oestrogen may not be the only factor related to the risk of thromboembolism; thus there was a significant deficit of reports associated with the combination of mestranol 100 mug. with norethynodrel 2.5 mg. and a significant excess of reports associated with the combination of ethinyloestradiol 50 mug. with megestrol acetate 4 mg. An excess of reports also occurred with other combined preparations containing megestrol acetate.The data obtained in earlier epidemiological studies were re-examined and, though no trend was obvious in any one of them, the combined results showed an excess of cases of thromboembolism at the highest dose of oestrogen.The finding of a positive correlation between the dose of oestrogen and the risk of coronary thrombosis is of special interest since previous studies have failed to provide clear evidence of a relationship between oral contraceptives and this condition.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5443406      PMCID: PMC1700093          DOI: 10.1136/bmj.2.5703.203

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  Influence of reduction of serum lipids on prognosis of coronary heart-disease. A five-year study using oestrogen.

Authors:  M F OLIVER; G S BOYD
Journal:  Lancet       Date:  1961-09-02       Impact factor: 79.321

2.  Puerperal thromboembolism and suppression of lactation.

Authors:  D G Daniel; H Campbell; A C Turnbull
Journal:  Lancet       Date:  1967-08-05       Impact factor: 79.321

3.  Thromboembolism and oestrogen therapy.

Authors:  J C Bailar
Journal:  Lancet       Date:  1967-09-09       Impact factor: 79.321

4.  Thromboembolism and oral contraceptives: an epidemiologic case-control study.

Authors:  P E Sartwell; A T Masi; F G Arthes; G R Greene; H E Smith
Journal:  Am J Epidemiol       Date:  1969-11       Impact factor: 4.897

5.  Puerperal thromboembolism.

Authors:  D G Millar; E G Robertson
Journal:  Br Med J       Date:  1968-11-16

6.  Venous effects of oral contraceptives.

Authors:  E C Grant
Journal:  Br Med J       Date:  1969-10-11

7.  Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age.

Authors:  W H Inman; M P Vessey
Journal:  Br Med J       Date:  1968-04-27

8.  Puerperal thromboembolism in relation to the inhibition of lactation by oestrogen therapy.

Authors:  T N Jeffcoate; J Miller; R F Roos; V R Tindall
Journal:  Br Med J       Date:  1968-10-05
  8 in total
  85 in total

Review 1.  Complications of systemic oral contraceptive therapy: Neoplasm--breast, uterus, cervix and vagina.

Authors:  M A Sperling
Journal:  West J Med       Date:  1975-01

2.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

3.  Oral contraceptives and death from myocardial infarction.

Authors:  J I Mann; W H Inman
Journal:  Br Med J       Date:  1975-05-03

4.  Oestrogenic potency and oral contraceptives.

Authors: 
Journal:  Br Med J       Date:  1975-06-21

Review 5.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

6.  Myocardial infarction in young women with special reference to oral contraceptive practice.

Authors:  J I Mann; M P Vessey; M Thorogood; S R Doll
Journal:  Br Med J       Date:  1975-05-03

7.  Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.

Authors:  Saad A W Shakir; Deborah Layton
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  The "top 50": a perspective on the BMJ drawn from the Science Citation Index.

Authors:  B Dixon
Journal:  BMJ       Date:  1990-10-03

Review 9.  Contraception.

Authors:  A Szarewski; J Guillebaud
Journal:  BMJ       Date:  1991-05-25

10.  Monitoring of adverse reactions to drugs in the United kingdom: some illustrative examples of the work done by the committee on safety of drugs.

Authors:  M P Vessey
Journal:  Proc R Soc Med       Date:  1970-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.